Stress Response Studies
Free Shipping on orders over $200
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
Selank is a calming, focus-supporting peptide researched for easing anxiety and sharpening cognition — without the sedation or dependence associated with traditional anti-anxiety drugs.
Synthetic tuftsin-derived heptapeptide
The pathways Selank acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Research indicates Selank modulates GABAergic neurotransmission, including GABA-A receptor activity and expression of GABAergic system components. This mechanism is associated with the anxiolytic effects observed in preclinical animal models and early clinical studies, without the sedative or dependency concerns seen with classical benzodiazepines.
Selank research demonstrates upregulation of brain-derived neurotrophic factor (BDNF) expression and enhancement of enkephalin metabolism. BDNF supports neuroplasticity and synaptic maintenance. Stabilization of enkephalin levels may contribute to the observed mood and cognitive effects in preclinical studies.
Selank is derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a proline-glycine-proline extension that enhances stability. Research demonstrates it modulates cytokine production including IL-6, IL-1β, and TNF-α expression, supporting its investigation as an anxiolytic with immunomodulatory properties.
The main areas Selank is being studied for — and the study-reported figures behind them.
Preclinical studies demonstrate anxiolytic effects in elevated plus maze and open field tests, attributed to GABAergic modulation. Selank shows anxiolytic activity comparable to diazepam without sedative side effects in rodent models.
Semenova et al. 2010Research reports improved learning and memory consolidation in animal models of stress-induced cognitive impairment. BDNF upregulation and enkephalin stabilization are proposed as underlying mechanisms supporting synaptic plasticity.
Kozlovskaya et al. 2008Studies report Selank modulates expression of interleukin-6, TNF-α, and interferon signaling pathways, consistent with its tuftsin-derived immunomodulatory origin. Investigated as a model for peptide-based neuroimmunomodulation research.
Zozulya et al. 2012Gene expression studies identify Selank-induced changes in transcription of genes related to serotonin, dopamine metabolism, and synaptic plasticity. Provides a molecular pharmacology research framework for peptide-based anxiolytics.
Inozemtseva et al. 2009An interactive 3D model rendered from the compound record — rotate and explore its structure.
C33H57N11O8
Every batch of Selank is sent to an accredited independent laboratory before it ships. Here is what we screen for.
| Chemical Name | Thr-Lys-Pro-Arg-Pro-Gly-Pro (Selank) |
| Sequence | H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH |
| Molecular Weight | 751.88 Da |
| Molecular Formula | C33H57N11O8 |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (Lyophilized) | -20°C for long-term stability |
| Storage (Reconstituted) | 2–8°C, use within 30 days |
| Solubility | Water or bacteriostatic water |
| COA | Included with every order |
Selank is a synthetic heptapeptide (7 amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), which is a natural fragment of IgG immunoglobulin. A Pro-Gly-Pro extension was added to increase the peptide's stability and half-life. Selank is approved in Russia as an anxiolytic drug for generalized anxiety disorder and neurasthenia.
Selank's anxiolytic effects are attributed to multiple mechanisms. Research indicates it modulates GABA-A receptor expression and GABAergic neurotransmission, similar to but distinct from benzodiazepines. It also upregulates BDNF (brain-derived neurotrophic factor), stabilizes enkephalin levels by inhibiting enkephalinase, and modulates serotonin and dopamine metabolism — creating a multi-target anxiolytic profile.
No. Selank is not approved by the FDA or the European Medicines Agency (EMA). It is approved in Russia under the brand name Selank for anxiety and neurasthenic conditions. Western clinical trial data is very limited, and most published research originates from Russian institutions. It is sold here for in vitro research use only.
Research suggests Selank modulates GABAergic activity through a different mechanism than benzodiazepines. Preclinical studies show anxiolytic effects without the sedation, motor impairment, or physical dependence observed with classical benzodiazepines. Selank appears to act as an anxioselective agent — reducing anxiety-related behaviors without producing sedation at effective doses in rodent models.
Selank is derived from tuftsin, a natural tetrapeptide with well-documented immunostimulatory properties. Research demonstrates Selank modulates cytokine production (IL-6, TNF-α, interferon signaling) and may act as a neuroimmune bridge. This dual neurological and immunological activity makes it of interest in neuroimmunomodulation research, investigating links between anxiety, stress, and immune function.
Lyophilized Selank should be stored at -20°C away from moisture and light. Once reconstituted in sterile or bacteriostatic water, it should be kept at 2–8°C and used within 30 days. The Pro-Gly-Pro C-terminal extension improves Selank's resistance to proteolytic degradation compared to tuftsin, contributing to greater stability in biological research conditions.
Independent published research indexed from PubMed and peer-reviewed journals — not Eon Peptides claims.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
